Predict your next investment

Syapse company logo
INTERNET | Internet Software & Services / Healthcare
syapse.com

See what CB Insights has to offer

Founded Year

2008

Stage

Series G | Alive

Total Raised

$169.5M

Last Raised

$68M | 1 yr ago

About Syapse

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying next-generation sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations.

Syapse Headquarter Location

303 2nd St., South Tower Suite 650

San Francisco, California, 94107,

United States

650-924-1461

Latest Syapse News

Syapse Extends Collaboration with Pfizer to Continue to Generate Real-World Evidence in Breast Cancer

Jan 20, 2022

San Francisco, California, UNITED STATES SAN FRANCISCO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Syapse® , a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced that Pfizer will continue working with Syapse to advance the use of real-world data (RWD) from the Syapse Learning Health Network™ (LHN), as an extension of the organizations’ ongoing collaboration . “Real-world evidence is a critical element to better understanding the treatment journeys of people living with cancer – allowing us to make smarter decisions, appropriately accelerate medicine development and personalized care, and helping ensure that patients receive the right medicines at the right time,” said Andy Schmeltz, Global President & General Manager, Pfizer Oncology. “We look forward to our continued collaboration with Syapse and its network of health system partners to analyze real-world data in breast cancer.” This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021. Additionally, Syapse will maintain clinical abstractions resources to continue to grow the breast cancer data cohort, expand research questions that can be answered, and provide Pfizer with in-depth, aggregated insights. As the foundation for continuing to provide data-enabled insights and services to Pfizer, Syapse will utilize its internal data platform to integrate, normalize, de-identify, and manage LHN data. Capabilities of the data platform include: Clinical Integrations: Integration with IT clinical systems across the LHN Molecular Lab Integrations: Integration with health system and commercial molecular diagnostic laboratories to support the ingestion of structured molecular results Third-Party Data Sources: Syapse invests in strategic partnerships with select third-party data sources that have significant overlap with the LHN to augment and strengthen the quality, completeness, breadth, and longitudinally of the LHN available to Pfizer. Data Improvement Collaboration: Collaboration to iteratively improve the quality of data. “We could not be more pleased to continue this meaningful research with Pfizer Oncology. The depth and breadth of the Syapse network present an opportunity to generate an unparalleled understanding of the oncology patient experience,” said Ken Tarkoff , chief executive officer, Syapse. “Further, we are proud to know that this high-quality data is simultaneously being shared among stakeholders within the LHN to improve cancer care through industry collaboration.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Syapse

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Syapse is included in 7 Expert Collections, including Digital Health.

D

Digital Health

12,378 items

Startups recreating how healthcare is delivered

C

Clinical Trials Tech

318 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

8,323 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

V

Value-Based Care & Population Health

656 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Syapse Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Syapse Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.